Edesa Biotech Reports FY2025 Results, Initiates Vitiligo Study and Validates Respiratory Therapeutic

Edesa Biotech reported a 30% increase in total operating expenses to $7.9 million for FY2025. The company initiated manufacturing activities for its dermatology drug candidate, EB06, in nonsegmental vitiligo patients and reported positive results for its respiratory program, paridiprubart (EB05). Edesa is exploring development and commercialization partnerships for paridiprubart and seeking non-dilutive support and collaborative arrangements.